Monitor cash burn rate and initiation of AP-SA02 Phase 3 trial. The $25M loan buys time but adds significant interest expense and secured debt, increasing risk of dilution or default if milestones slip. Stock likely to react negatively to continued losses and going-concern overhang.
Price Chart
Executive Summary
Armata Pharmaceuticals entered into a $25M secured credit facility with Innoviva at 14% interest to fund AP-SA02 development, while reporting a Q1 2026 net loss of $115.3M (largely non-cash fair value charges) and cash of only $4.8M pre-loan. The loan extends runway but adds significant leverage, and the company's ability to achieve Phase 3 milestones remains uncertain given ongoing cash burn.
Key Financial Metrics
Key Facts
- Entered $25M secured term loan with Innoviva at 14.0% interest, maturing January 11, 2029
- Q1 2026 net loss of $115.3M vs $6.5M in Q1 2025, driven by $101M non-cash change in convertible loan fair value
- Cash and cash equivalents of $4.8M at March 31, 2026, down from $8.7M at December 31, 2025
- Operating loss widened to $8.8M from $8.2M in Q1 2025
- FDA granted Fast Track and QIDP designations for AP-SA02; Phase 3 study expected H2 2026
- Loan is secured by substantially all assets and includes covenants restricting operations
Financial Impact
$25M debt added at 14% interest; net loss of $115.3M in Q1 2026
Risk Factors
- High cash burn with only $4.8M pre-loan; new debt at 14% interest rate
- Going concern risk remains; total stockholders deficit of $311.6M
- Clinical and regulatory uncertainty for AP-SA02 Phase 3
- Secured loan covenants may restrict operational flexibility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-060299 |
| Document: armp-20260512xex99d1.htm | 0001104659-26-060299 |
| Document: armp-20260512x8k.htm | 0001104659-26-060299 |
| Document: 0001104659-26-060299-index-headers.html | 0001104659-26-060299 |
| Document: 0001104659-26-060299-index.html | 0001104659-26-060299 |
| Document: 0001104659-26-060299.txt | 0001104659-26-060299 |
| 8-K Data (Synthetic) | 0001104659-26-060299 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $5.55 $4.26 | ▼ −23.24% | ▼ −23.35% | $3.52 (−36.58%) |
Jul 20, 2026 10w ago | 8-K | $5.06 $4.66 | ▼ −7.91% | ▼ −7.48% | $3.52 (−30.43%) |
May 13, 2026 20w ago | 8-K | $8.20 $8.23 | ▼ −0.37% | ▼ −1.08% | $3.52 (+57.07%) |
Apr 27, 2026 22w ago | 8-K | $11.00 $9.85 | ▼ −10.45% | ▼ −10.85% | $3.52 (−68.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access